Researchers are ramping up efforts to target tau for Alzheimer’s and other tauopathies.
Does a tau-based early diagnosis look more likely?
An active immunotherapy is coming to the fore as researchers continue to try novel therapies.
Could exosomes—tiny parcels extruded from cells—make for a blood-based Alzheimer’s marker?
Lifestyle changes to evade dementia, such as healthy eating and exercise, made a strong showing at the Alzheimer’s Association International Conference in Copenhagen, Denmark.
New data strengthens the evidence that dementia risk is dropping in developed countries, possibly due to better education and heart health.
A global effort to combat dementia has been conducting a yearlong series of events. Alzforum spoke with Dennis Gillings, who chairs the new World Dementia Council.
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
Could tweaking methodologies improve amyloid diagnosis and tracking?
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
Will an antibody signature make for a new Alzheimer’s diagnostic?
Tau and amyloid PET tracers demonstrate potential to sharpen the diagnosis of Alzheimer’s disease and frontotemporal dementias.
Researchers are increasingly branching out from their old focus on Aβ and tau to understand how these proteins intersect with physiological processes and new genetic regulatory mechanisms in the aging brain.